IN8bio, Inc. (INAB)
- Previous Close
1.0500 - Open
1.0200 - Bid 0.9721 x 100
- Ask 1.0600 x 100
- Day's Range
0.9900 - 1.0900 - 52 Week Range
0.6500 - 3.9500 - Volume
278,634 - Avg. Volume
344,580 - Market Cap (intraday)
44.586M - Beta (5Y Monthly) -0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.63
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
in8bio.comRecent News: INAB
Performance Overview: INAB
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INAB
Valuation Measures
Market Cap
43.94M
Enterprise Value
27.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.76
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.99
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-56.81%
Return on Equity (ttm)
-125.90%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.01M
Diluted EPS (ttm)
-1.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
21.28M
Total Debt/Equity (mrq)
19.62%
Levered Free Cash Flow (ttm)
-12.53M
Research Analysis: INAB
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell